Switch to
More onapp

Zenlabs Ethica Ltd

ZENLABS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹48 cr, stock is ranked 2,636
High RiskStock is 3.33x as volatile as Nifty
75.000.20 (+0.27%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹48 cr, stock is ranked 2,636
High RiskStock is 3.33x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
58.67
PB RatioPB Ratio
5.20
Dividend YieldDiv. Yield
Sector PESector PE
35.69
Sector PBSector PB
4.33
Sector Div YldSctr Div Yld
0.89%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Zenlabs Ethica Limited is an India-based marketing company. The Company is engaged in trading in a range of branded drugs, including gastrointestinal tract disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps and anti-bacterial drugs, nutraceuticals, and other. It has approximately five state-of-the-art manufacturing units. It operates through three divisions: Zenlabs, Coles Pharma and Mega Star. Zenlabs division provides various products, including Analgesics & Anti-Inflammatory, Skin Preparations, Neurological Disorders, Eye, Ear and Nasal Drops, Anti-Diabetic, Anti-Depressant, Anti-Infective, Anti-Emetic, Steroid & Anabolic Steroid, Anti-Hypertensive Drugs, Anti Allergic, Anti Cold & Cough Syrup, Nutraceuticals, Antacid, Enzymes & Appetite Stimulant, Ayurvedic Preparation, GIT Disorders, Soap, and Other Pharmaceutical Drugs. Coles Pharma division provides various products, including Analgesics & Anti-Inflammatory, Nutraceuticals, Skin Preparations and other.

Financial TrendFinancial statements 

201920202021202267.4660.0056.7669.181.27-0.740.770.83
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 7.09%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Cash Dividend 
Ex. DateJul 29, 2022

Interim • Div/Share: ₹ 0.25

Cash Dividend 
Ex. DateSep 20, 2017

Final • Div/Share: ₹ 0.25

See all events